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ABSTRACT
Indirubin is the active ingredient in the ancient herbal remedy, Danggui
Longhui Wan, which is used as an anti-leukemic, anti-inflammatory, and
detoxification treatment. Indirubin-3’-monoxime (IO) is the most widely studied of
the indirubin derivatives. Most have been shown to inhibit cyclin-dependent
kinases and glycogen synthase kinases, triggering cell cycle arrest and apoptosis
with different levels of activity depending on the particular structure. These
kinases inhibited by indirubin(s) play key roles in cellular proliferation and
immune functions, therefore synthetic indirubins may have significant
applications as therapeutic agents for cancer, inflammation, and neurological
diseases.
Indirubin is also a potent aryl hydrocarbon receptor (AhR) agonist. The
AhR is a cytosolic protein, which upon ligand binding is translocated to the
nucleus and acts as a transcription factor for genes involved in drug metabolism,
oxidative stress, and inhibitors of the cell cycle. Known anthropogenic ligands
(PCBs, dioxins, PAHs etc.) are mutagenic, carcinogenic, and immunotoxic. In
this study, I examined the effects of select indirubins on gene/protein expression
profiles, AhR activation, and cellular functions in the mouse macrophage cell line
RAW 264.7. Structure activity relationships (SAR) show that different derivatives
of indirubin may differentially affect AhR activation, kinase inhibition, and/or other
cellular functions, including intracellular killing of bacteria. The ultimate goal was
to identify a synthetic indirubin derivative that would be beneficial to cancer and
inflammation research without being overtly toxic.
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From this research, Indirubin-3’-(2,3 dihydroxypropyl)-oximether) (E804),
and 6-bromoindirubin-3-monoxime (BIO) were shown to be very potent AhR
ligands with strong anti-inflammatory properties. This study also shows that E804
has more clinical promise than its more famous counterpart indirubin-3’monoxime.
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LITERATURE REVIEW

The Institute of Hematology, Chinese Academy of Sciences (1976) treated
16 chronic myelogenous leukemia (CML) patients with ingredients from an
ancient medicinal recipe called Danggui Longhui Wan (DLW), and reported that 4
patients showed complete remission and 5 partial remission. The ancient remedy
is made from extracts of several indigo-producing plants including Polygonum
tinctorium, Isatis indigotica and Isatis tinctoria. According to the Chinese
Academy of Medical Sciences (1975), I. tinctoria extracts significantly prolonged
the life span of rats with Walker carcinosarcoma 256 tumors, whereas other plant
extracts from DLW did not. The anti-leukemic properties from DLW were found to
come from the ingredient Qing Dai which is made up of indirubin, an isomer of
indigo. Indirubin is a red colored bis-indole metabolite of tryptophan found in
indigo-producing plants (Wu et al., 1979). In a later clinical trial, 253 patients with
CML were given 150-200mg/day of indirubin synthesized from indigo blue. Over
60% of the patients showed at least partial remission (Reviewed in Xiao et al.,
2002). Although these findings were exciting, due to indirubin’s poor solubility
patients had severe gastrointestinal side-effects and were forced to stop
treatment (Zheng et al., 1979). Recently, several derivatives have been
synthesized to increase the efficacy of the compound and decrease the toxicity
side effects of indirubin.
The mechanisms of action which indirubin and its derivatives possess are
not well known. The 11 herb remedy, DLW has a broad list of pharmacologically
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relevant effects that could be exploited. Consumers also use the ancient herbal
medicine for its detoxification and anti-inflammatory properties in treating chronic
disease (Kunikata et al 2000). It is prudent to examine nutraceutical remedies not
only for safety and efficacy but for future drug therapies. One critical aspect for
this investigation is the effect indirubin has on gene expression, cellular signaling,
protein function, and inflammation in macrophages.
Activated macrophages display several important physiological functions
such as phagocytosis, antigen presentation, and release of a diverse arsenal of
biological mediators, for example, reactive oxygen intermediates and reactive
nitrogen species, cytokines, and hydrolytic enzymes (Reviewed in Billack 2006).
These actions make macrophages vital cells in the immune system, particularly
in their role in innate immunity. The broad and essential roles these cells play
make them attractive targets for therapeutic drug treatments.
A major aspect of innate immunity is the inflammatory response which
can be stimulated by diverse chemical, infectious, or mitogenic stimulants.
Mediators of the immune system include, chemokines, enzymes that promote
vascular permeability and migration of immunomodulators, chemoattractant
molecules responsible for the recruitment of neutrophils and monocytes, and the
inflammatory family of cytokines which include interleukin 1 (IL-1), IL-6, IL-18,
tumor necrosis factor α (TNF-α), colony stimulating factors (CSF) and many
others that regulate the duration and potency of the inflammatory response
(Reviewed in O’Shea et al., 2008; Jones et al., 2000). The innate immune system
is in close association with the more specific adaptive immune response. IL-18 is
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one of the cytokines produced during the inflammatory response involved in
crucial crosstalk in promoting T helper cell 1 response in the adaptive immune
response (Wuttge et al., 2003).
Hematopoietic stem cells develop into monocytes in the presence of
macrophage colony stimulating factor and granulocyte-macrophage colony
stimulating factor within the bone marrow. Monocytes enter the blood stream and
migrate to tissues where they differentiate into macrophages. Macrophages are
activated by the recognition of pathogen associated molecular patterns (PAMPs),
which are conserved sequences on microbial non-self molecules, by pattern
recognition receptors like toll like receptors (TLRs). To date there are at least 13
different TLRs in mammals (Roach et al., 2005) that bind to PAMPs and selfaltered molecules (Akira et al., 2004). Toll-like receptor 4 (TLR4) is a
transmembrane receptor that recognizes several ligands notably
lipopolysaccharide (LPS). Ligand (LPS) binding initiates the recruitment of
various adaptor proteins to the cytosolic Toll-IL-1 receptor (TIR) domain which
activates a signaling pathway leading to the activation and subsequent nuclear
translocation of nuclear factor kappa B (NF-кB). The induction of inflammatory
genes as well as genes that regulate cell cycle progression, apoptosis and cell
differentiation are expressed depending on the nature and specific manner in
which ligand binds (Yan et al., 2007). Other toll-like receptors also mediate
inflammation, for example, TLR1 and TLR2 ligand binding also initiates the
translocation of NF-κB promoting the gene expression of IL-6 (Krishnan et al.,
2007).
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The role cytokines play in the immune response has been an area vastly
studied particularly in inflammation. Interleukins, interferons, and colonystimulating factors bind to type I and II cytokine receptors (Boulay et al., 2003)
that commonly have a cytoplasmic Janus kinase (Jak) family associated with it.
Specific receptor/cytokine binding activates Jak kinases to phosphorylate
tyrosine residues in the receptor cytoplasmic domain creating a docking site for
Src homology 2 domain proteins, like Stat transcription factors (signal
transducers and activators of transcription). This cascade of cytokine signaling is
known as the JAK-STAT pathway (Kisseleva, et al., 2002). There are seven
members of the Stat family of DNA-binding proteins, Stat1, Stat2, Stat3, Stat4,
Stat5a, Stat5b, and Stat6, which regulate gene expression by the specific
cytokine bound. A hallmark of acute inflammation is a change in plasma proteins
called acute phase proteins; IL-6 is the principle cytokine responsible for the
concentration level change of these proteins (Gauldie et al., 1987). Agents that
inhibit IL-6 production show promise in clinical trials of patients with arthritis and
chronic inflammatory diseases (Crocker et al., 2003).
In addition to cytokines macrophages produce enzymes that are key
components in innate immunity that result in the production of nitric oxide, a
potent player in inflammation. There are three types of nitric oxide synthases,
NOS1 and NOS3 also known as neuronal NOS (nNOS) and endothelial NOS
(eNOS) are named for cells they were characterized in. NOS2 better known as
inducible nitric oxide synthase (iNOS) is not constitutively expressed but
synthesized upon activation in cells. iNOS acts on the amino acid L-arginine to
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convert it to L-citrulline and nitric oxide (NO) and released in what is called the Larginine-NO pathway (Moncada et al., 1989; Moncada et al., 2002). Regulation
of iNOS is achieved by cytokines (Liew et al., 1997) and mediating the stability
and activation of mRNA. Several transcription factors regulate the iNOS gene
promoter including NF-кB and signal transducer and activator of transcription 1
(STAT1) (Reviewed in Tripathi et al., 2007). LPS alone is capable of inducing
Nos2 gene in the mouse macrophage cell line RAW 264.7; however, in most
other cell lines cytokines and other stimulating factors are needed (MacMicking
et al., 1997). Knockout mice deficient of the iNOS gene show greater
susceptibility to infection and an increase in fatality when they encounter bacteria
compared to their wild-type controls (MacMicking et al., 1997; MacMicking et al.,
1995).
Nitric oxide is a toxic free radical gas that is cell permeable and can react
with molecular oxygen to form reactive nitrogenous intermediates (Eiserich et al.,
1998). These highly reactive species are capable of killing or dramatically
reducing the replication of microbial agents including viruses, bacteria, and fungi.
On the contrary, however, the overproduction of NO can lead to necrosis of
healthy tissue and host toxicity (Laskin et al., 1996). The role of the small NO
molecule has drastic effects on virtually ever level of the inflammatory response
including vascular permeability, vasodilatation, leukocyte migration and
adhesion, and microbe clearance (Guzik et al., 2003).
Danggui Longhui Wan has been used for centuries in the treatment of
chronic inflammatory disease, although the means of action remain elusive, it is
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reasonable to look at the NF-кB signaling pathway, also known as the central
mediator of the immune response. It is a key transcription factor that when
stimulated expresses several inflammatory genes. NF-кB is a member of the Rel
domain-containing proteins family, consisting of a heterodimer of p50 and p65. It
is found in the cytoplasm of cells in association with IкB which holds it in its
inactive form. It has been reported that there are over 150 extracellular means of
activation of this pathway including numerous pathogens, cytokines, and stress
stimuli. Only when activated does IкB kinase (IKK) phosphorylate IкB, signaling
its degradation to the proteosome, thereby disassociating it from its inhibitory
hold on the heterodimer. This unmasks the translocation factor enabling the p65
subunit to be phosphorylated this leads to the translocation of NF-kB to the
nucleus. NF-kB is responsible for the regulation and activation of many diverse
genes and pathways, including the expression of many immune modulators,
inflammatory cytokines, stress responses, and cell proliferation and
differentiation molecules (Li et al 2002). The transcription factor regulates
antiapoptotic, inflammatory and stress related genes including SURVIVN, Bcl,
Cox-2, and cell cycle genes cyclin D1 and c-MYC (Sethi et al, 2006).
Following earlier observations the effects of indirubin-3’monoxime and
other indirubin derivatives on the function of RAW 264.7 macrophages, and
consequently the inflammatory response were investigated; focusing on several
key modulators of the inflammatory response and report the effect that indirubin
and its soluble derivatives have on this important aspect of immunity.
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In 1999, Hoessel et al. reported on a finding that would give great insight,
interest, and understanding into indirubin and its derivatives. They showed the
co-crystallization structure of indirubins and cyclin-dependent kinases (CDK1 and
CDk2), key factors in the progression of the cell cycle. This revealed a
competitive inhibition of the indole compounds with ATP for the catalytic binding
site of the kinase. Cyclin-dependent kinase inhibitors halt the cell cycle, therefore
inducing apoptosis, making them excellent candidates for cancer therapy.
The mammalian cell cycle is composed of four stages; two gap stages G1
and G2, a DNA synthesis stage S, and mitosis, M. G1 is a critical checkpoint in
the progression of a cell from the resting G0 phase through to S phase. The cycle
is under tight control through the degradation and production of regulatory
molecules creating an oscillating concentration of protein subunits called cyclins
which function to activate cyclin dependent kinases (CDKs). The heterodimer of
cyclin/CDK then phosphorylates key proteins, involved in the progression of the
cycle, activating or inactivating them in a series of orchestrated regulated events
through the stages of the cell cycle. The Gap1 cyclin, cyclin D, binds to CDK4
and CDK6 which are involved in the checkpoint regulation of G1 progression into
the S phase. CDK4 (6)/cyclin D phosphorylates many substrates including the
retinoblastoma protein (Rb). The phosphorylation of Rb (pRb) releases its
repression leading to the activation of the E2F family of transcription factors
which are responsible for the expression of various genes that are involved in cell
cycle progression (Reviewed in Johnson et al., 1999). The over-expression of
cyclin D mRNA and/or protein levels is seen in over 50% of breast cancers (Roy
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et al., 2006). Therefore, finding a high affinity inhibitor of this cyclin subunit could
be pivotal in the future of breast cancer treatment, as well as other cancers.
Hoessel et al., (1999) also reported on the kinase selectivity of various
derivatives acting on several CDK/cyclin complexes. Derivatives have
preferential binding affinities for specific CDKs or other structurally related
kinases based on the chemical makeup and confirmation of the derivative. Indigo
did not show an inhibition for the enzymes tested, furthering the evidence that the
active anti-leukemic component of Danggui Longhui Wan is indirubin and not
indigo. Polychronopoulos et al., (2003) tested numerous indirubin derivatives
against CDK1/cylin B, CDK5/p25, and GSK-3β, showing that the difference in the
chemical substitutions of indirubin have different affinities to kinases. The
selectivity is based on the substituted group that is in contact with the CDK-ATP
catalytic binding pocket.
Leclrec et al., (2000) also reported that indirubin and some of its soluble
derivatives are potent inhibitors of glycogen synthase kinase-3β (GSK-3 β) and
CDK5 by competing with ATP in the active site of the kinase, similar to its
inhibition on CDK1 and CDK2 as reported by Hoessel et al., (1999). This finding
is of much interest due to GSK-3 and CDK5’s role in neurological disorders like
Alzheimer’s disease and bipolar disease. GSKs are responsible for numerous
distinct physiological pathways including cell cycle progression (Diehl et al.,
1998), WNT signaling pathway (Willert et al., 1998), and inflammation (Woodgett
et al., 2005). Imahori et al (1997) reported that the two kinases responsible for
the formation of neurofibrillary tangles (NFT) are GSK-3B and CDK5, which is
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one of the hallmarks of Alzheimer’s disease. The neurological disease is
comprised of paired helical filaments from the abnormal hyperphosphorylation of
Tau protein by the glycogen synthase and cyclin-dependent-5 kinases (Ferrer et
al., 2005). The ability of a compound to inhibit such phosphorylation could lead to
promising agents in the fight against Alzheimer’s and other such diseases.
Another key turning point in the study of indirubin and its derivatives came
in 2001 (Adachi et al.) from a finding that indirubin purified from human urine has
the ability to bind to the cytosolic aryl hydrocarbon receptor (AhR). Polygonum
tinctorium extracts in addition to alleviating inflammation and cancer are also
used for enhancing detoxification processes, suggesting that this plant contains
compounds that induce the family of cytochrome P450 enzymes through the aryl
hydrocarbon receptor AhR. Adachi et al (2001) showed that indirubin is the most
likely candidate because it is an AhR ligand capable of inducing CYP1A, a phase
I drug metabolizing enzyme of the P450 family (Kawajiri et al., 2007). Kawanishi
et al., (2003) showed that using a reporter yeast construct that indirubin is a
potent AhR ligand. The CYP1A1 gene expression is induced over twelve fold
compared to DMSO (carrier control) in human U937 macrophages upon
treatment with indirubin-3’-monoxime (Springs et al., 2006).
The immunotoxic, homeostatic, and biologic consequences of many
halogenated aromatic hydrocarbons (HAH), polychlorinated biphenyls (PCB),
and other xenobiotic pollutants are a direct effect of their interaction with the AhR
(Hahn, 1998). The AhR is in the basic helix-loop-helix-PER-ARNT-SIM (bHLHPAS) superfamily of transcription factors (reviewed in Schmidt et al., 1996). The
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bHLH family members have two distinct highly conserved domains, the basicregion involved in DNA binding and the helix loop helix region involved in protein
interactions. There are two PAS domains that help facilitate the interaction
between the receptor and Ah receptor nuclear translocator (ARNT) and ligand
binding (Emma et al., 1992; Coumailleau et al., 1995). The AhR is also known as
the dioxin receptor for its high affinity to the ligand 2,3,7,8-tetrachlorodibenzo-pdioxin (dioxin or TCDD) which achieved notoriety in the 1970's when it was found
to be a contaminant in the herbicide Agent Orange. TCDD was also used as
chemical warfare agent during the Vietnam War (Reviewed in Frumkin, 2003).
In the inactivated state, the AhR is a cytosolic ligand-activated
transcription factor found within most tissues and cells. It is associated with heat
shock protein 90 (HSP-90) homodimer (Chen et al., 1994), a p23 chaperone
(Cox et al., 2004), and an immunophilin-related protein XAP-2 (Meyer et al.,
1998). Upon ligand binding, the coupled proteins are disassociated and the AhRligand complex is translocated to the nucleus where it binds with AhR nuclear
translocator (ARNT). The ligand/receptor/ARNT complex binds to xenobiotic
response element (XRE), a cassette of specific DNA sequences upstream of
various genes such as drug metabolizing enzymes CYP1A1, glutathione Stransferase (GST) (Rushmore et al., 1990) and UDP-glucoronsyltransferase
(UGT) (Iyanagi et al., 1986) increases the transcription rate of these genes.
(Reviewed in Shimba et al., 2001; Nohara et al., 2005; Nguyen, et al., 2007;
Marlowe et al., 2005). These phase II enzyme genes associate with the Nrf2
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gene battery which binds to antioxidant response elements (AREs) encoding
several enzymes related to oxidative stress (Kohle et al., 2007).
The aryl hydrocarbon receptor is classified as an orphan receptor, in that
a known endogenous ligand has not yet been found. However, recently it was
discovered that indirubin, found naturally in human urine, binds the AhR and thus
may be an endogenous ligand for the receptor (Adachi et al., 2001; Spink et al.,
2003, Schnitzer et al., 2005). Knockaert et al., (2004) showed that Io and various
other derivatives, including methylated indirubins, rapidly translocate the
cytosolic AhR to the nucleus. This was an interesting finding because the
substituted methyl group interferes with the molecules ability to bind to the cyclindependent kinase catalytic site, and therefore is not an inhibitor of the kinase.
This suggests that some of the effects on cytotoxicity and cell cycle arrest are
independent of CDK inhibition and could be AhR-dependent.
This is alarming because most anthropogenic compounds that bind to the
AhR, for example TCDD and PCB-126 are highly mutagenic, immunotoxic, and
carcinogenic (Hankinson, 1995 and Andersson et al 2002). Aryl hydrocarbon
receptor ligands can have both antagonistic and agonistic effects on the AhR
signaling pathway (Nishiumi et al, 2008). Some ligands that bind to the receptor
could induce apoptosis and therefore cause growth inhibition in some tumors and
cancer cells while other ligands promote tumorogenesis (Bradshaw et al 2002,
Damiens et al 2001, and Koliopanos et al 2002). The alteration of this pathway in
a non-toxic manner could lead to another mechanism in which indirubins could
arrest the cell cycle and be beneficial pharmacological agents.
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Although the anti-cancer properties of indirubins, via CDK-inhibition, are
the subject of increased area of studies, the effects on inflammation and
detoxification mechanisms are not well established. This dissertation investigates
the effects of indirubin derivatives, in comparison with PCB-126 a known AhR
ligand, on gene/protein expression, AhR activation, and cellular function using a
murine macrophage cell line RAW 264.7.
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Indirubin (IR)

Indirubin-3’-monoxime (IO)

6-Bromoindirubin-3’-monoxime
(BIO)

Indirubin-3’-(2, 3 dihydroxypropyl)oximether (E804)

Figure 1. The structure of indirubin and indirubin derivatives.
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INTRODUCTION
The multibillion dollar Nutraceuticals industry is growing rapidly, especially
in the use and production of ancient herbal remedies. Some of the most well
known of these products are oriental supplements and teas which are readily
consumed by the American public on the marketing promise of anti-cancer, antiinflammation, and anti-disease that leads to longevity and health. The public
lacks an appropriate knowledge of the ingredients, effects, or modes of action of
these holistic medicines. Many herbal remedies consist of several ingredients
leading to the activation of different cellular pathways and “healing” capacities.
Recently there has been a push to isolate the key active compounds and test
their efficacy and safety. This study presented herein describes the effects of one
such natural components, on gene expression, cellular signaling and finally on
select immunologic cellular functions.
The Chinese Academy of Medicine identified Qing Dai (indigo naturalis) to
be the active component of Danggui Longhui Wan, an ancient Chinese herbal
tea used to treat several conditions, including neoplasia, detoxification, and
chronic inflammation. The ingredients are derived, in part, from the plants
Polygonum tinctorium (Polygonaceae) and Istasis indigotica (Brassicaceae) (Wu
et al., 1979). The minor constituent indirubin (IR), an indigo blue isomer, was
purified from the active Qing Dai substance, and found to be the compound
responsible for the anti-leukemic properties that the Chinese tea seemed to
possess. Indirubin, a metabolite of the amino acid tryptophan, has a colorful red
appearance formed by the spontaneous dimerization of its colorless precursors
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indoxyl and isatin (reviewed in Hoessel et al., 1999). In some rare cases, patients
with catheters get purple urine bag syndrome (PUBS), and will produce purple
colored urine in the urinary bag, this was found to consist of indirubin and indigo
(Dealler et al., 1988). In patients with PUBS tryptophan is metabolized by graham
negative bacteria that act to degrade indican into indigo and indirubin producing
the purple coloration (Vallejo-Manzur, 2005). The exact mechanism in which
indirubin is formed from tryptophan varies among its natural sources which
include; indigo producing plants, Tyrian purple-producing mollusks, wild-type and
recombinant bacterial strains and mammalian urine including human and bovine
(Maugard et al., 2001; reviewed in Gillam et al., 2000; Meijer et al., Bhushan et
al., 2000; 2003; Adachi et al., 2001).
Over the past two decades indirubin has sparked much interest as a
pharmacological agent, especially in the use in cancer treatment with the finding
that indirubin arrests the cell cycle by binding to and inhibiting cyclin-dependent
kinases (Hoessel et a., 1999). Early clinical trials showed great promise in
treating chronic myelogenous leukemia (CML) as well as granulocytic leukemia.
In the patients with CML who received indirubin, 26% showed complete
remission and 33% partial remission (Gan et al., 1985; reviewed in Hoessel et
al., 1999). However, the compound is poorly soluble and can cause gastrointestinal and toxicity problems. In an effort to minimize side effects and increase
efficacy of the compound, soluble derivatives have been synthesized, most
notable indirubin-3’-monoxime (IO). IO has been used in many laboratories to
study the compounds modes of action and potential for various therapeutic
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medicines in cancer, inflammation, and neurological disorders. Some of the
newly synthesized derivatives have similar effects in the body without the
insolubility side effects associated with indirubin (Marko et al., 2001; Guengerich
et al., 2004).
Recently, it was reported that indirubin, found naturally in human urine,
binds with high affinity to the aryl hydrocarbon receptor (AhR) (Adachi et al.,
2001; Spink et al., 2003, Schnitzer et al., 2005). The fact that indirubin was found
naturally in mammalian urine gives intrigue to the possibility of an endogenous
ligand for the AhR. To date the AhR is considered an orphan receptor, in that a
known endogenous ligand has not been found. Several halogenated aromatic
hydrocarbon (HAH) and polycyclic aromatic hydrocarbons (PAH) that are
considered environmental pollutants bind to the AhR. The most potent and
famous of which is 2,3,7,8-tetrachlorodibenzene-p-dioxin (TCDD or dioxin).
Binding of aromatic hydrocarbons to the receptor initiates the AhR signaling
pathway leading to a wide range of toxic and carcinogenic responses (Marlowe
et al., 2005).
The AhR is a member of the PER ARNT SIM (PAS) superfamily of
proteins (Gu et al., 2000). It is found in the cytoplasm of most cells in an
inactivated state held by chaperone p23 and heat shock proteins (Chen et al.,
1994; Cox et al., 2004). Ligand binding dissociates these proteins from the
receptor freeing it to translocate the nucleus. Once in the nucleus the ligand/AhR
forms a heterodimer with aryl hydrocarbon receptor nuclear translocator (ARNT).
These complexes can then bind to and manipulate the xenobiotic response
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element of genes, including drug-metabolizing enzymes such as the cytochrome
P450 family including CYP genes (Hahn, 1998). Knockaert et al., (2004) showed
that IO and various other derivatives translocate the cytosolic AhR to the
nucleus. Further, IO has been found to increase the gene expression of CYP1A1
in U937 human macrophage cell line (Springs et al., 2006)
Immune suppression, reproductive, and developmental disorders are
associated with anthropogenic AhR ligand exposure (Holsapple et al., 1996).
Therefore, it is alarming that these natural compounds could bind and trigger
such toxic results. However, in recent years it has become evident that ligands
of the AhR not only trigger toxicant enzyme activities but independent of and in
combination with these activation pathways trigger other signal transduction
pathways as well (Puga et al., 2002). AhR signaling has been shown to regulate
developmental cues, cell cycle progression, and homeostasis along with
chemical toxicity (Reviewed in Nguyen et al., 2008). Several studies have shown
that the AhR has a role in cell cycle regulation, although the mechanisms are not
well known. Ge et al. (1998) reported on a direct protein-protein interaction
between the AhR and the retinoblastoma protein (Rb), a critical molecule in the
cell cycle. In response to ligand binding there is an increase in gene expression
of p27, a CDK2 inhibitor, halting the cell cycle in G1. The dual mechanism of
indirubins is shown in Figure 1 (Knockaert et al., 2003). Dependent on the
chemical makeup and confirmation of the synthesized derivative (Figure 3.) the
affinity may be greater for AhR binding, cyclin-dependent kinase inhibition, or
other cellular pathways. A key question for the future of this area of research is to
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find a molecule with the beneficial pharmacology effects for medicinal drug
therapy, without the traditional AhR immunotoxicity and mutagenesis.
Although the adverse effects of anthropogenic compounds have been
studied, very little is known about the effects endogenous ligands have on the
function of macrophages or the immune system. Previous work has shown that
macrophages are susceptible to AhR activation in terms of phagocytic activity
(Tweari et al., 1979; van Grevenynghe et al., 2003), intracellular killing, ability to
present antigen, and produce cytokines (van Grevenynghe et al., 2003). This
study will describe the effects of indirubin derivatives on gene expression, AhR
signaling pathway, and on select immunologically relevant cellular functions in
RAW 264.7 macrophages.
A key turning point in the story of indirubin came in 1999 when Hoessel et
al. established that indirubin and some of its derivatives (indirubins) can
competitively bind to the ATP-binding pocket of cyclin-dependent kinases (CDK1
and CDK2) by means of van der Waals interactions and hydrogen bonding,
thereby inhibiting their role in cell cycle progression. This finding is the probable
mechanism through which the anti-leukemic properties of the herbal medicine
are seen. Although the exact pathway and mechanism of action is not clear, it is
becoming evident that indirubin(s) act to arrest cells and induce apoptosis by
means of CDK inhibition, making them a prospective anti-cancer compound.
The discovery of the cyclin-dependent kinase inhibitory activity of indirubin
peaked interest in the use and identification of indirubins that have high affinity
binding to CDKs, therefore becoming potential anti-cancer targets. Indirubin(s)
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have been found to inhibit proliferation in many human cancer cell lines (Libnow
et al., 2008), including human tumor cells, through the arrest in G2/M phase by
blocking the action of CDK2, CDK1 and cyclin B kinase (Marko et al., 2000).
Recently, Kameswaran et al., (2008) showed that IO increased cell death and
apoptosis in human laryngeal carcinoma cells by inducing p21, a CDK inhibitor
protein and further by the inhibition of cyclin D1. Springs et al., (2006) showed
that Io reduced the p21 gene expression in human U937 cell line. The sudden
influx of the synthesis of various indirubin derivatives has led to numerous
reports of selective and potent inhibition of specific cancers. For example,
meisoindigo has been reported to inhibit microtubule assemblage and DNA
synthesis in tumor cells (Ji et al 1991) and decrease c-myb gene expression
thereby inducing leukemic cell differentiation (Liu et al., 1996). Indirubin-N’glycosides (Libnow et al., 2008) have showed great promise in arresting several
cell lines notably the breast cancer cell line MCF-7. Kim et al., (2007) reported
antitumor activity with 5’-nitro-indirubinozime, 5’-fluoro-indirubinoxime, and 5’
trimethylacetamino-indirubinoxime in a Sprague-Dawley rat tumor model.
Knockaert et al., (2004) showed that IO and various other derivatives,
including methylated indirubins, rapidly translocate the cytosolic AhR to the
nucleus. This was an interesting finding because the substituted methyl group
interferes with the molecules ability to bind to the cyclin-dependent kinase
catalytic site, and therefore is not an inhibitor of the kinase (Figure 3). This
suggests that some of the effects on cytotoxicity and cell cycle arrest are
independent of CDK inhibition and could be AhR-dependent. This is alarming
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because most compounds that bind to the AhR, for example TCDD and PCB-126
are highly immunotoxic and carcinogenic (Hankinson, 1995 and Andersson et al
2002). However, it has been reported that aryl hydrocarbon receptor ligands can
have both antagonistic and agonistic effects on the AhR signaling pathway
(Nishiumi et al, 2008). Some ligands that bind to the receptor could induce
apoptosis and therefore cause growth inhibition in some tumors and cancer cells
(Bradshaw et al 2002, Damiens et al 2001, and Koliopanos et al 2002). The
alteration of this pathway in this manner could lead to another mechanism in
which indirubins could arrest the cell cycle and be beneficial pharmacological
agents.
In addition to IO’s role in halting the cell cycle and inducing apoptosis,
indirubins have been reported to be an anti-inflammatory agent. Hamburger et al
(2002) reported that leaf extracts from I. tinctoria, an indigo producing plant,
significantly inhibited cyclooxygenase-2 (COX-2) and iNOS in mast cells.
Recently a study using extracts as a topical cream on induced contact dermatitis
in humans showed significantly smaller increase of visual inflammation
(Heinemann et al., 2004). Kunikata et al (2000) showed a suppression of
interleukin 6 and interferon gamma inflammatory cytokines in mouse splenocytes
and human myelomonocytic HBL-28 cells, respectively. They also reported on
the inhibition of indirubin on induced delayed-type hypersensitivity as
demonstrated by 2,4,6-trinitro-1-chlorobenzene ear swelling in mice. These
studies suggest indirubin derivatives are potent anti-inflammatory compounds.
Sethi et al., (2006) showed that the inflammatory signaling pathway nuclear
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factor kappa B (NF-kB) is inhibited with the treatment of indirubin through the
inhibition of IκB kinase and other phosphporylating events. A similar molecule
Indol-3-carbinol, a byproduct in plants and cruciferous vegetables, suppresses
NF-kB and IkB kinase activation, leading to the suppression of several gene
products including cyclin D1, COX-2, and anti-apoptotic factors (Takada et al.,
2005).
For the first time the effects indirubins have on gene expression, protein
expression, and the function of key components of the inflammatory response at
a cellular level are presented using a relevant RAW 246.7 macrophages in the
presence and absence of LPS.
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Figure 2. The dual mechanisms in which indirubins may induce cell cycle arrest
in dividing cells. (Knockaert et al., 2004)
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Figure 3. Study by Knockaert et al. (2004) on indirubins in comparison with
TCDD on the interactions in two AhR reporter systems and two kinase assays.
EC50 and IC 50 values were calculated from dose-response curves in µM amounts.
* represents compounds inactive at the highest indicated concentration tested.
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MATERIALS AND METHODS
Cells and cell culture
The murine macrophage cell line RAW 264.7 was obtained from the
American Type Culture Collection (Manassas, VA) and maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Cellgro) supplemented with 10% fetal bovine
serum (Atlas; Fort Collins CO), 10mM HEPES solution, 100mM L-glutamine
penicillin streptomycin solution, 3 g/L glucose, and 1.5 g/L of sodium bicarbonate,
each from Sigma (Sigma Aldrich, St. Louis MO, USA). Cells were grown at 37°C
with 5% CO2 in Corning 75cm2 culture flasks. Unless otherwise noted, each
experiment had two regimes. A 24 hour regime consisted of cells treated with
compound alone or simultaneously with compound and ultra pure
lipopolysaccharide (LPS) (Alexis Biochemical, San Diego CA, USA). A 48 hour
regime entailed treatment of cells with compound for 48 hours or with compound
and LPS for the last 24 hour of incubation.

Chemicals
Specific indirubins and PCB congeners were selected based on the literature
and predicted structure-activity-relationships (SARs) relevant to AhR binding.
Compounds were first solubilized in DMSO (Sigma Aldrich) to a stock
concentration of 10-2 M and diluted to a final working concentration using
unsupplemented media.
IR: Indirubin (synthetic) (Alexis Biochemical, San Diego, CA)
IO: Indirubin-3’-monoxime (A.G. Scientific Inc, San Diego, CA)
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E804: Indirubin-3’-(2,3 dihydroxypropyl)oximether (Alexis Biochemical,
San Diego, CA)
5Iodo: 5-Iodoindirubin-3’-monoxime (Alexis Biochemical, San Diego, CA)
PCB-126: 3,3',4,4',5-pentachlorobiphenyl (Ultra Scientific, North Kingston
RI, USA)
BIO: 6-Bromoindirubin-3’-oxime (GSK-1 Inhibitor X) (EMD Biosciences
Inc, San Diego, CA)
5-Iodo: Indirubin-5-sulphonate. Na (Alexis Biochemical, San Diego, CA)
PCB-104: 2,4,6,2',6'-pentachlorobiphenyl (Ultra Scientific, North Kingston,
RI)
DMSO: Dimethyl sulphoxide Hybri-Max® (Sigma Aldrich)
LPS: Lipopolysaccharide from E. coli, Serotype R515 (Re) (ultra pure,
TLR4grade™) (Alexis Biochemical, San Diego, CA)
PMA: Phorbol 12-myristate 13-acetate (A.G. Scientific, San Diego, CA)

Experiment: 1. Effective dosage and cell viability
Cytotoxicity – MTT assay
Cellular respiration as an indication of viability was measured by MTT (3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. RAW 264.7
macrophages and D74 rat glioma cells from the American Type Culture
Collection (Manassas, VA) were plated into 96 well Costar plates at 1x105 cells
per well in 100µl of DMEM media. After 4 hr incubation at 37°C for adherence,
compounds and DMSO carrier control were added in triplicate at a concentration
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at serial dilutions of from 10-5 M/well. The cells incubated with compound for
either 24 or 48 hr. Four hours before termination of experiment each well
received 20µl of MTT at 5mg/ml in unsupplemented media. After centrifugation,
the supernatant for each well was discarded and the formazan solubilized with
100µl of acidified isopropanol. Following a brief period of shaking, the optical
density for each well was read at wavelength of 550λ on an uQuant microplate
reader (BioTek Instruments Inc). Data were expressed as percentage of the
control O.D. values for each experiment.

ApoScreen™ Annexin V Apoptosis Assay
Since the MTT assay quantify only cellular respiration and viability, and
not cell death due to apoptosis, apoptosis was quantified by measurement of
externalized phosphatidylserine residues as detected using an ApoScreen™
Annexin V Apoptosis Kit (Southern Biotech, AL, USA). Raw 264.7 murine
macrophages were seeded at 2.5 x 106 cell/well in 24 well plates for 3 hr for
adherence, and treated with 1µM indirubin-3’-monoxime, E804, or PCB-126
alone, or compound and LPS (1µg/ml) for 24 hr. Other compounds were not
further tested based on the MTT results. After treatment cells were washed with
ice-cold PBS and 500µl of Annexin V binding buffer. Binding buffer (100µl) was
added to all wells, along with 5µl of Annexin V-FITC was added, and the mixture
incubated for 15 min on ice in the dark. Without washing, 380µL of cold 1X
binding buffer and 10uL of PI were added to each. After washing the samples,
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aliquots were processed by flow cytometer using FACScan™ (BD Biosciences,
San Jose, CA) and 10 000 cells were scored in each event.

Experiement: 2. Gene expression
rRT PCR Arrays for Stress & Toxicity
Murine macrophage RAW 264.7 cells were seeded at 5 X 106 cells/ml in
75 cm2 culture flasks (Corning Inc., NY) and allowed to adhere to flask surfaces
for 3 hours. Cells were then treated for 24 hr with 1µM of indirubin-3’-monoxime,
E804, and PCB-126 or compound and LPS. The adhered macrophages were
scraped from the flask surface using BD FalconTM cell scraper (BD Biosciences,
Bedford, MA) and harvested by centrifugation. TRI-reagent® was added (1ml) to
all cell pellets and the mixture was homogenized by gentle pippeting several
times. The homogenate was incubated at room temperature for 5 min and 0.2 ml
chloroform added. After incubating the mixture for 15 min, the samples were
centrifuged at 12,000 g for 15 min at 4°C. The aqueous phase was transferred to
a new 1.5 ml microcentrifuge tube precipitated with 0.5 ml isopropyl over a 10
min period, then centrifuged again at 12,000 rpm for 15 min and redissolved in
DEPC-treated water. After collecting 1mg RNA from each tube, Genomic DNA
contamination was eliminated by using Genomic DNA elimination mixture
(SuperArray Bioscience Corporation, Frederick, MD) and cDNA synthesis was
carried using the RT cocktail (SuperArray Bioscience Corporation, MD). Mouse
Oxidative Stress RT2 Profiler PCR Array and RT2 Real-Timer SyBR Green/qPCR
Master Mix were purchased from SuperArray Bioscience Corporation (Frederick,
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MD). PCR was performed on BioRad iQ5 real-time PCR detection system
(Applied Biosystems). For data analysis the ∆∆Ct method was used; for each
gene fold-changes were calculated as difference in gene expression between
untreated controls and treated cell cultures. A positive value indicates gene upregulation and a negative value indicates gene down-regulation.

Experiment: 3 AhR activation
Translocation of AhR
Activation of the aryl hydrocarbon receptor (AhR) was determined by
fluorescent microscopy (Knockaert, et al., 2004). RAW 264.7 cells were grown in
minimum essential medium (Cellgro) without phenol red supplemented with 10%
FBS (Atlas; Fort Collins CO), 10mM HEPES solution, 100mM L-glutamine
penicillin streptomycin solution, 3 g/L glucose and 1.5 g/L of sodium bicarbonate
each from Sigma (Sigma Aldrich, St. Louis MO, USA). 100µl of macrophages
were seeded at 1 x 106 cells/ml in each well of an 8-chambered glass slide
(Fisher) and were allowed to adhere for 4 hours. Cells were treated for 4 hours
with 1µM of IO, E804, PCB126, and PCB104. Because the platform design could
accommodate an additional compound, cells were also treated with 1µM BIO.
The macrophages were fixed with 3% methanol free paraformaldehyde in HBSS
for 30 min followed by a brief 5 min treatment with 0.1% sodium borohydride to
quench auto-fluorescence. Cells were permeablized with 0.1% Triton X (Sigma)
in HBSS for 30min, then blocked with 3% Fraction V bovine serum albumin for 2
hours at room temperature in a humidified chamber. Polyclonal anti-AhR primary
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antibody (Biomol Research Laboratories, Plymoth PA, USA 1:100) was
incubated overnight at 4°C rocking slowly. FITC conjugated secondary antibody
was added followed by DAPI labeling. Cells were mounted in 50% glycerol and
observed on a microscope equipped with a Canon camera on a Zeiss Axiovert
135 fluorescent microscope (Zeiss Gruppe, Germany).

Experiment: 4 Cellular functions
Nitric Oxide production
RAW 264.7 murine macrophages were seeded in 96 well COSTAR plates
at 1x105 cells per well in Minimum Essential Medium-alpha (MEM) without phenol
red (Gibco-Invitrogen), supplemented with 4µM L-Arginine. Cells were treated
with 1µM IO, BIO, E804, PCB-126 or compound and LPS. 100µl aliquots were
removed from the conditioned medium and incubated in 96 well plates at room
temperature for 15 min with an equal volume of Griess reagent (equal parts
Reagent 1; N-(1-naphthyl)ethylenediamine dihydrochloride (NED) and Reagent
2; Sulfanilamide) (Ding et al, 1988). The absorbance (OD) was measured using
an uQuant microplate reader (BioTek Instruments Inc) at 550nm. A standard
curve of known concentration of nitric oxide was made using sodium nitrite. The
values were averaged and then plotted as a stimulation index against the control
(Burleson et al 1995).
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iNOS Western Blot
Western blot analysis for inducible nitric oxide synthase (iNOS), the
enzyme responsible for the production of NO, was determined from RAW
264.7cell lysates harvested after treatment with IO, BIO, E804, PCB-126 and
compound with LPS treated cells after 24 hr and 48 hr. The cells were lysed in
ice cold lysis buffer (50mM Tris, 150 mM NaCl, 1% IGEPAL, 0.1% SDS, pH8)
supplemented with HALT protease inhibitors (Pierce). The samples were
centrifuged at 15,000 for 10 min and the supernatant collected. Total protein was
measured using BCA protein reagent assay (Pierce, Rockford IL). Equal
concentration (30µl) of protein for each treatment were loaded on lanes of a 420% SDS-PAGE criterion gel (Biorad) at 200 volts then transferred to a
nitrocellulose membrane (Millipore Corp, Billerica MA). After blocking with BSA
containing 0.01% gelatin, the membranes were probed with antibody specific for
iNOS (rabbit anti-iNOS, Signal Transduction Labs, Lexington KY: 1:500) followed
by goat anti rabbit secondary antibody (1:1000). The blots were then developed
with NitroBT/BCIP substrate solution.

Interleukin-6 ELISA
Interleukin-6 (IL-6) production by RAW 264.7 cell supernatant followed by
treatment was determined by a mouse READY-SET-GO IL-6 ELISA system
(eBioscience). Briefly, cells were seeded onto a 96 well plate and incubated with
compound in the presence or absence of LPS for 24hr or 48hr. One hundred µl
of supernatant were added to a precoated capture antibody Costar maxisorb
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plate and incubated overnight at 4°C. Detection antibody was added followed by
treatment of avidin-HRP and a colorimetric substrate solution. A phosphoric acid
stop solution was added, and the plate read at 450nm on an uQuant microplate
reader (BioTek Instruments Inc). Concentrations of IL-6 were plotted against the
standard curve of known concentrations of mouse IL-6 supplied by the
manufacturer.

Measurement of ROS
The ability of indirubin(s) to either enhance total reactive oxygen species
(ROS) production or to modify PMA induced ROS was determined by
florescence resulting from the oxidation of dichlorodihydrofluorescein diacetate,
H2DCFDA (Molecular Probes, Eugene, OR) as described by Ding et al. (1988).
Briefly, cells were seeded onto black 96 well plates at 1 x 105 cells/well using
MEM without phenol red (Invitrogen). After treatment with compounds or
compounds with LPS for 24h or 48h, 22µl of 10-4 H2DCFDA was added to all
wells for 30 min. PMA (10-6M) was added to appropriate wells and incubated for
an additional 30 min before fluorescent 2’7’-dichlorofluorescin was measured on
a FLX-800 microplate fluorescence reader (BioTek Instruments, Inc) at excitation
485nm and emission 528nm (Mattson et al., 1995, revised by Henning et al.,
2002). Data was presented as RFU compared to their controls.
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Phagocytosis
Phagocytosis was measured by a modification of previously described
methods (Bozzaro et al., 1987; Peracino et al., 1998). RAW264.7 cells were
added to 96-well round bottom plates at 1 x 105 cells per well in 100µl of
complete media. Cells then received 100µl of media containing 1µM Io, E804,
BIO, PCB-126, PCB-104 or carrier control in the presence or absence of LPS.
After treatments for 24 hr or 48 hr, cells were washed with PBS. Washed
fluorebrite carboxylate YG, 1 micron, microspheres (Polyscience, Inc Warrington
PA, USA) diluted in 50mM Na2HP04, were added to RAW 264.7 cells in the same
round bottom 96 well plates at a ratio of 100:1 (1 x 107 beads to 1 x 105 cells per
well), and centrifuged for 5 min for maximal contact. The plates were incubated
at 37°C for 45min or 90min. Extracellular microspheres (those beads that were
not phagocytosized) were cleared through extensive washes in a series of
centrifugations. Phagocytosis was stopped by the addition of 100µl of ice cold
PBS with 1mM CaCl2 and MgCl2. Plates were centrifuged, the well contents
removed by aspiration, and replaced with a Ca++/Mg** – free HBSS containing
0.01% trypsin. Cells were then transferred to an all-black 96 well plate. Trypan
blue (2mg/ml) dissolved in 20mM citrate and 150mM NaCl, pH 4.5, was added
for 5 minutes to quench extracellular fluorescence. Plates were then read on a
FLx-800 fluorescent spectrophotometer at an excitation wavelength of 485nm
and emission wavelength 528nm. Data were recorded as RFUs relative to the
control.
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Lysozyme assay
Lysozyme activity was measured in RAW 264.7 cell lysates based on
procedures of Parry et al., (1965) and modified by Burton et al., (2002). Cells
were seeded onto COSTAR 6 well plates at 2 x 106 per well in DMEM complete
media and treated with 1µM IO, E804, PCB-126, PCB-104, or carrier control in
the presence or absence of LPS for 24 and 48 hr. Cells were then lysed and the
protein concentration normalized to 1mg/ml. One hundred µl of cell lysate, in
triplicate, were added onto 96 well plates followed by the addition of 200 µl of
2mg/ml of heat killed Micrococcus lysodietikus (MP Biomedicals, Solon, Ohio
USA) in 0.01 sodium phosphate buffer, pH 4.0. The plates were read at
wavelength 450nm every 5 min for 30minutes, then again at 10 minute intervals
for an additional 30 minutes. One unit of lysozyme activity was defined as a
decrease in absorbance of 0.001 min-1.

Bactericidal Assay
Intracellular killing of XL-1 Blue E.Coli (Stratagene, La Jolla, CA, USA) by
RAW 264.7 cells was measured using a novel approach based on Boleza et al.,
(2001) and communication with Stratagene. RAW 264.7 cells were seeded onto
96 well plates at a concentration of 1 x 105 cells/well under both the 24 hr and 48
hr treatment regimes with 1µM Io, BIO, E804, PCB-126 or carrier control (with
and without 1µM PMA). Bacteria were grown overnight in LB broth without
antibiotic, centrifuged and resuspended in sucrose-magnesium buffer (SM buffer)
to an O.D. of 0.5 at 600nm, which is equivalent to 4 x 108 cells (technical
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sources from Stratagene). Bacteria were added to the pretreated cells at a ratio
of 25:1 and incubated for 180 minutes at 37°C. Extracellular bacteria were
washed away extensively with PBS, and residual bacteria killed by the addition of
20µl of 10000U Penicillin and 10g/mL steptomyocin solution (Sigma Aldrich) for
10 min. Cells were then permeablized with 0.1% Tween-20 in PBS for 15 min to
release the engulfed bacteria. Viable bacteria were grown up in LB broth for 12
hours at 37°C. The survival of bacterial was measured by a MTT assay. The
results are presented as the mean of percentage of control treated cells for three
experiments.
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RESULTS

Cytotoxicity and effective dosage
In studies described herein, the anti- or pro-inflammatory effects of select
indirubin derivatives and reference PCBs were examined in the murine
macrophage cell line RAW 264.7. Cells were treated with compounds alone or
with LPS for 24 or 48 hours and endpoints relevant to gene expression,
transcription factor activation, and functional endpoints were measured. Since
the literature on indirubins suggests a pro-apoptotic effect in various cell lines,
cytotoxicity was first determined in an effort to find a suitable dose for
subsequent experiments. As indicated in Figure 4, RAW 264.7 cells are very
sensitive to indirubins, while the reference cell line D74, a rat glioma line, is
relatively resistant (Figure 5). Based on the MTT assay, exposure to levels less
than 1µM of tested compound were not cytotoxic in terms of affecting cellular
respiration. Therefore, 1µM was used for all subsequent experiments and
regimes to determine gene and protein expression, as well as functional cellular
assays.
To confirm that 1 uM was not only non-cytotoxic, but non-pro-apoptotic as
well, annexin-V binding was quantified. The flipping of phosatidylserine to the
outer cell membrane is indicative of early apoptosis and can be detected through
the binding and subsequent staining of annexin-V-FITC. As apoptosis continues
the cell membrane becomes degraded allowing molecules to enter the nuclear
membrane. In late apoptosis, cells that have lost membrane integrity can be
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measured by propidium iodide staining of DNA. The results of annexin-V staining
coincide with the MTT assay results in that most of the cells after 24h exposure
to compounds (Figure 6) or compounds with LPS (Figure 7) are viable and not
labeling annexin-V.
QrRT PCR Arrays for Stress and Toxicity
RT2 Profiler™ PCR microarrays (SuperArray Bioscience Corporation,
Frederick, MD) for stress and toxicity profile the expression of 84 genes involved
in oxidative or metabolic stress, proliferation and carcinogenesis, growth arrest
and senescence, inflammation, and apoptosis. The Array was used to determine
the effect of indirubin-3’-monoxime, E804, and PCB-126 under the 24 hr regime
on gene expression in the absence or presence of LPS. The select functional
gene groupings are shown in Table 1. The corresponding tables (Table 2-11)
represent fold changes in gene expression compared to appropriate control
(cells alone, or cells treated with only LPS); a negative number indicates a downregulation, while a positive number is indicative of an induced gene.
A notable effect is seen in the expression of inflammatory genes. As
expected LPS activated macrophages show the increased expression of several
inflammatory genes (Table 2). Cells treated with indirubin-3’-monoxime alone
show a decrease in the expression of the NOS2, while E804 and PCB-126 both
down regulated chemokine ligand 10, TNFb, and Serpine1 compared to cells
treated without compound. In cells simultaneously activated with LPS (Table 3)
indirubin-3’monoxime and E804 shut down the expression of several
inflammatory genes, including IL-6, while PCB-126 did not.
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Of interest in the proliferation and carcinogenesis gene groupings (Table
4) Indirubin-3’-monoxime and E804 decrease the expression of cyclin C and
cyclin D1, further E804 drastically inhibits the gene expression of E2F
transcription factor 1. The expression of proliferation and carcinogenesis genes
in macrophages activated with LPS consistently showed a decrease in most of
the genes tested (Table 5). The gene expression of growth arrest and
senescence, surprisingly, showed an overall decrease in regulation in both
compound alone and LPS activated cells, notably, p21 and p53, two important
genes in the regulation of progression of the cell cycle (Table 6 and Table 7).The
genes involved in apoptotic signaling varied in the expression results, all three
compounds showed an upregulation of caspase 1 and caspase 8 (Table 7) while
Bcl2-like 1 and NF-kB inhibitor were downregulated. The suppression of NF-kB
inhibitor, not surprisingly, due to its important role in many cellular functions,
Nfkb1 was induced in most treatment scenarios. LPS-activated macrophages
displayed an overall decrease in the expression of apoptotic genes, E804 and
PCB-126 showed a dramatic downregulation of Bcl211 (Table 8). However, E804
did induce Bax.
E804 was the only compound to show an increase in the expression of the
cytochrome P450 family of genes (Table 10) while heme oxygenase 1, an
inducible gene in response to oxidative stress, showed an increase in expression
in all compounds in all regimes (Table 11).
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Translocation of AhR
To confirm the activation and subsequent translocation of the aryl
hydrocarbon receptor from the cytoplasm to the nucleus in RAW 246.7
macrophages, fluorescent microscopy was used. The derivatives IO (Figure 9),
BIO (Figure 10), and E804 (Figure 11) each translocated the AhR to the nucleus,
as well as the well documented AhR ligand PCB-126 (Figure 12). As expected,
the AhR in control treated cells (Figure 8) and PCB-104, a non-planar, non AhRbinding PCB congener, (Figure 13) did not leave the cytoplasm and translocate
to the nucleus.

Measuring NO, IL-6, and ROS concentrations
To determine the effects of indirubins on key players of the inflammatory
response, several assays were employed. The measurement of nitrate, a stable
form of nitric oxide was achieved using Greiss reagent. E804 was the only
compound that significantly lowered the stimulation index for NO produced by
LPS-activated macrophages in both time regimes, (Figure 14 and Figure 15).
iNOS protein expression, as measured by SDS-PAGE and western blotting,
confirmed the NO production assay. iNOS protein concentrations were reduced
by exposure to E804 (Figure 16). E804 also significantly decreased the
expression of IL-6 (Figure 17 and Figure 18) in LPS activated cells. The 48 hr
regime showed a decrease in activity for all compounds exposed to activated
macrophages (Figure 18).
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The measurement of intracellular ROS was determined by RAW 264.7
cells ability to cleave H2DCFDA. Most of the indole compounds showed an
increase in the production of ROS after 24h of exposure (Figure 19). However,
cells exposed to indirubin-3’-monoxime and BIO under the 48h regime showed a
decrease in ROS production (Figure 20).

Functional Immunological Endpoints
Three functional endpoints were selected due to their importance in
cellular immunocompetency. Cellular expression of lysozyme activity,
phagocytosis of fluorescent latex beads, and intracellular bactericidal assays
were selected and optimized. To determine lysozyme enzymatic activity the
ability for RAW 246.7 macrophage cell lysates to clear Micrococcus lysodietikus
was measured. In LPS-activated cells, E804 decreased the units of enzymatic
activity after the 24 hr of exposure (Figure 21). Further, after 48 hr (Figure 22)
cells treated with compound alone and with compound and LPS showed a
decrease in enzymatic activity.
The phagocytic ability of RAW264.7 macrophages to engulf 1 micron
latex beads after 45 minutes was hindered by all indole compounds tested
(Figure 23) but not as drastic after 90 minutes (Figure 24). These indirubins
inhibited intracellular killing of E. Coli in macrophages in the 24 hr regime not
activated by PMA (Figure 25). E804 was the only compound that showed
significant increase in the percentage of surviving bacteria (suppressed
intracellular killing) for the 48h regime.
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Figure 4. Cytotoxicity of indirubins, PCB-126, and PCB-104 to RAW 246.7 cells
after treatment for 24 hours and 48 hours as determined by MTT assay. Data
represents the percent survival means of three experiments +/- standard error.
DMSO was included as carrier control.
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Figure 5. Cytotoxicity of indirubins, PCB-126, and PCB-104 to D74 glioma cells
after treatment for 24 hours as determined by MTT assay. Data represents the
percent survival means of three experiments +/- standard error. Tributyltin
chloride (TbT) was included as positive cellular toxicity control.
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Figure 6. Effects of 1µM of compounds on apoptosis in RAW 246.7 macrophages
as measured by flow cytometry with annexin V (x-axis) and propidium iodide (yaxis). I- Early apoptosis II-Late apoptosis III-Viable cells, not undergoing
apoptotic events IV- Early apoptosis.
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Figure 7. Effects of 1µM of compounds + LPS on apoptosis in RAW 246.7
macrophages as measured by flow cytometry with annexin V -labeling (x-axis)
and propidium iodide-labeling (y-axis). I- Early apoptosis II-Late apoptosis IIIViable cells, not undergoing apoptotic events IV- Early apoptosis.
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Table 1. Functional Gene Groupings of the Mouse Stress and Toxicity Pathway
Finder™ RT2 Profiler™ PCR Array.

Inflammation: Ccl21b, Ccl3 (MIP-1a), Ccl4 (MIP-1b), Csf2 (GM-CSF), Cxcl10
(Scyb10), Il1a, Il1b, Il6, Il18, Lta (TNF b), Mif, Nfkb1, Nos2 (iNOS), Serpine1
(PAI-1).
Proliferation and Carcinogenesis: Ccnc (cyclin C), Ccnd1 (cyclin D1), Ccng1
(cyclin G), E2f1, Egr1, Pcna.
Growth Arrest and Senescence: Cdkn1a (p21Waf1/p21Cip1), Ddit3
(GADD153/CHOP), Gadd45a, Igfbp6, Mdm2, Trp53 (p53).
Apoptosis: Anxa5 (annexin v), Bax, Bcl2l1 (bcl-x), Casp1 (Caspase1/ICE),
Casp8 (caspase8/FLICE), Fasl (Tnfsf6), Nfkbia (ikBa/Mad3), Tnfrsf1a (TNFR1),
Tnfsf10 (TRAIL), Tradd
Oxidative or Metabolic Stress: Cryab (a-Crystallin B), cytochrome p450 family,
Ephx2, Fmo1, Fmo4, Fmo5, Gpx1 (glutathione peroxidase), Gpx2, Gsr
(glutathione reductase), Gstm1 (glutathione S-transferase mu1), Gstm3, Hmox1,
Hmox2, Mt2, Polr2k (Mt1a), Por, Sod1, Sod2.
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Table 2. Altered inflammatory gene expression in RAW 264.7 macrophages
treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or PCB-126 as
determined by PCR array analysis. Data represents the fold change difference in
RFU between compound and control treated cells.

GENE
Chemokine
ligand 21b
Chemokine
ligand 3
Chemokine
ligand 4
ColonyStimulating
factor 2
Chemokine
ligand 10
Interleukin 18
Interleukin 1
alpha
Interleukin 1
beta
Interleukin 6
Tumor
necrosis factor
beta
Macrophage
migration
inhibitory factor
Nuclear factor
kappa B (p105)
Inducible nitric
oxide synthase
Serpine 1

LPS
1.03

IO
-1.06

E804
2.68

PCB126
1.23

7.17

1.01

4.81

-1.01

190362

25710

633278.7

19791

27.28

-1.06

2.68

1.23

3.34

1.14

-72.65

-158.9

-1.4
169.9

-1.19
9.32

-1.16
2.68

-1.06
9.44

35.45

-1.21

-2.29

1.05

67.89
1.53

-1.2
-1.35

2.38
-4.10

1.29
-2.2

350089

167864

4862.56

331157

16920

9244

6500

7706

10.19

-239.23

2.36

-1.55

3.46

1.65

3.31

-2.35
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Table 3. Altered inflammatory gene expression in RAW 264.7 macrophages
treated simultaneously with 1µM LPS and indirubin-3’-monoxime, E804, or PCB126 for 24h as determined by PCR array analysis. Data represents fold change
difference in RFU between compound + LPS and LPS treated cells.

GENE
Chemokine
ligand 21b
Chemokine
ligand 3
Chemokine
ligand 4
ColonyStimulating
factor 2
Chemokine
ligand 10
Interleukin 18
Interleukin 1
alpha
Interleukin 1
beta
Interleukin 6
Tumor
necrosis factor
beta
Macrophage
migration
inhibitory factor
Nuclear factor
kappa B (p105)
Inducible nitric
oxide synthase
Serpine 1

LPS
1.03

IO+LPS
-1.89

E804+LPS
-1.47

PCB126+LPS
1.13

7.17

-1.67

-1.7

1.01

190362.2

-1.31

-38.6

-1.21

27.29

-2.83

-1.64

1.28

3.34

-2.17

-928.16

1.16

-1.4
169.9

-2.06
-1.28

-1669.83
-14.75

1.17
-146.55

35.45

-1.43

-1.89

1.5

67.89
1.53

-140.87
-2.94

-1.94
1.27

1.46
-1.47

350089.6

-3.47

-1.39

1.06

16920.76

-1.63

-1.48

-2

10.19

-1.27

-1.35

-1.16

3.46

-1.51

-1.01

-1.34
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Table 4. Altered proliferation and carcinogenesis gene expression in RAW 264.7
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or
PCB-126 as determined by PCR array analysis. Data represents the fold change
difference in RFU between compound and control treated cells.

GENE

LPS

IO

E804

PCB126

Cyclin C

-1.21

-1509

-335.31

1.01

Cyclin D1

-1.51

-2366

-3.564.05

-1.06

Cyclin G1

-1.07

-15.34

7.2

1.4

E2f transcription
factor 1

-1.18

1.09

-968.65

-1.62

Early growth
response 1

8989

1208

2.68

3734

Proliferating cell
nuclear antigen

15.98

4.91

-5

-1967
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Table 5. Altered proliferation and carcinogenesis gene expression in RAW 264.7
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime,
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents
the fold change difference in RFU between compound + LPS and LPS treated
cells.

GENE

LPS

IO+LPS

E804+LPS

PCB126+LPS

Cyclin C

-1.21

-1385.62

-1072.65

-649.7

Cyclin D1

-1.51

-7792.47

1.02

-1.13

Cyclin G1

-1.07

-26.45

-11.9

-4197.59

E2f
transcription
factor 1
Early growth
response 1

-1.18

-1.55

-3201.7

-1.08

8989

-1.83

-1.81

1.26

Proliferating cell
nuclear antigen

15.98

-8.46

-1.27

-1.06
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Table 6. Altered growth arrest and senescence gene expression in RAW 264.7
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or
PCB-126 as determined by PCR array analysis. Data represents the fold change
difference in RFU between compound and control treated cells.

GENE

LPS

IO

E804

PCB126

Cyclindependent
kinase inhibitor
1a (p21)
DNA-damage
inducible
transcript 3
(Ddit3)
Growth arrest
and DNAdamageinducible 45
alpha
Insulin-like
growth factor
binding protein 6
Transformed
mouse 3T3 cell
double minute 2
p53

-1.06

-4.26

-3.92

1.12

2.09

-56.39

-7.77

-1.2

2.75

-22.54

-5.34

-1.2

1.01

-1.68

2.68

1.33

25458

10705

2.68

14380

1.15

-5.93

-6387

-1.05

56

Table 7. Altered growth arrest and senescence gene expression in RAW 264.7
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime,
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents
the fold change difference in RFU between compound + LPS and LPS treated
cells.

GENE

LPS

IO+LPS

E804+LPS

PCB126+LPS

Cyclindependent
kinase inhibitor
1a (p21)
DNA-damage
inducible
transcript 3
(Ddit3)
Growth arrest
and DNAdamageinducible 45
alpha
Insulin-like
growth factor
binding protein 6
Transformed
mouse 3T3 cell
double minute 2
p53

-1.06

-3.34

1.13

1.09

2.09

-20.46

-2.3

1.19

2.75

-9.07

-1.64

1.44

1.01

-1.89

-1.46

1.13

25458

-1.67

-1.95

-17.66

1.15

-8.69

-1.35

-1.12
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Table 8. Altered apoptosis gene expression in RAW 264.7 macrophages treated
for 24h with1µM LPS, indirubin-3’-monoxime, E804, or PCB-126 as determined
by PCR array analysis. Data represents the fold change difference in RFU
between compound and control treated cells.

GENE

LPS

IO

E804

PCB126

Annexin A5

91288

94751

1733843

98147

Bcl2-associated
X protein

-1.05

-1.22

3.95

-11926

Bcl2-like 1

2.55

-1364

-302.91

-1.55

Caspase 1

6462

2076

446703

1.33

Caspase 8

418.16

399

265.75

420

Fas ligand

1.01

-1.68

2.68

1.33

Nuclear factor
kappa B
inhibitor
Tumor necrosis
factor receptor
1a
Tumor necrosis
factor receptor
10
TNFRSF1Aassociated
death domain

2.88

-6.07

-13.53

1.3

1.2

-1.32

-756

-2.3

2.13

2.61

2.68

4.6

-1.0

-1.1

5.74

1.38

58

Table 9. Altered apoptosis gene expression in RAW 264.7 macrophages treated
simultaneously with 1µM LPS and indirubin-3’-monoxime, E804, or PCB-126 for
24h as determined by PCR array analysis. Data represents the fold change
difference in RFU between compound and LPS treated cells.

GENE
Annexin A5
Bcl2-associated
X protein
Bcl2-like 1
Caspase 1
Caspase 8
Fas ligand
Nuclear factor
kappa B
inhibitor
Tumor necrosis
factor receptor
1a
Tumor necrosis
factor receptor
10
TNFRSF1Aassociated
death domain

LPS
91288
-1.05

IO+LPS
-1.12
1.04

E804+LPS
-1.09
-21897.7

PCB126+LPS
1.19
-13263.5

2.55
6462
418.16
1.01
2.88

-3879.33
-3.25
-1.68
-1.89
-6.27

-1.35
-1.39
-1.37
-1.46
1.01

-1818.97
1.26
1.06
1.13
1.15

1.2

-1.72

1.1

-2129.69

2.13

-1.88

-3.08

1.02

-1.0

-1.64

-1.5

1.13
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Table 10. Altered oxidative and metabolic gene expression in RAW 264.7
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or
PCB-126 as determined by PCR array analysis. Data represents the fold change
difference in RFU between compound and control treated cells.

GENE
Crystallin B

LPS
1.01

IO
-1.68

E804
2.68

PCB-126
1.33

Cytochrome
P450 family
Epoxide
hydrolase 2
Flavin containing
monoxygenase 1
Flavin containing
monoxygenase 4
Flavin containing
monoxygenase 5
Glutathione
peroxidase 1
Glutathione
peroxidase 2
Glutathione
reductase
Glutathione Stransferase mu1
Glutathione Stransferase mu3
Heme
oxygenase 1
Heme
oxygenase 2
Metallothionein 2

1.01

-1.68

2.68

1.33

1.01

-1.68

2.68

1.33

1.01

-1.68

2.68

1.33

5.23

-1.68

2.68

1.33

-1.75

-243.35

-54.06

1.38

-1.37

-2.41

-32.58

1.09

-2.21

1.3

-3.42

-1.01

-1.05

-23.22

2.25

-1.74

-1.15

-2281

-507

-1.51

1.01

-1.68

2.68

1.33

1.01

2729

1582.53

1.33

1.07

-2.28

1.10

1.33

1.52

-1.27

-4.96

-1.02

-1.21

-237

8.9

1.62

1.29

-1.68

1.81

-1578

66465

312

323782

99398

2.05

-7.26

-457.67

-922

Polymerase II
polypeptide K
P450
oxidoreductase
Superoxide
dismutase 1
Superoxide
dismutase 2
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Table 11. Altered oxidative and metabolic stress gene expression in RAW 264.7
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime,
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents
the fold change difference in RFU between compound + LPS and LPS treated
cells.

GENE

LPS

IO + LPS

E804 + LPS

Crystallin B

1.01

-1.89

-1.46

PCB-126 +
LPS
1.13

Cytochrome
P450 family
Epoxide
hydrolase 2
Flavin containing
monoxygenase 1
Flavin containing
monoxygenase 4
Flavin containing
monoxygenase 5
Glutathione
peroxidase 1
Glutathione
peroxidase 2
Glutathione
reductase
Glutathione Stransferase mu1
Glutathione Stransferase mu3
Heme
oxygenase 1
Heme
oxygenase 2
Metallothionein 2

1.01

-1.89

-1.46

1.13

1.01

-1.89

-1.46

1.13

1.01

-1.89

-1.46

1.13

5.23

-9.79

-7.58

-1.19

-1.75

-155.48

-1.21

1.86

-1.37

-3.67

-1.48

-1.47

-2.21

1.49

-2.52

1.41

-1.05

-3.51

1.84

1.84

-1.15

-2.17

-1.36

-1.18

1.01

-1.89

-1.46

1.13

1.01

6529.36

6448.8

6798.29

1.07

-2.51

-1.15

1.07

1.52

-1.6

-1.55

225352

-1.21

-326.06

-1.06

1.2

1.29

-1.32

1.1

1.02

66465

-147.65

-1.49

-1.03

2.05

-6.77

-1.69

-2189.75

Polymerase II
polypeptide K
P450
oxidoreductase
Superoxide
dismutase 1
Superoxide
dismutase 2
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A

B

C

D

10µm

Figure 8. Nuclear translocation of AhR in RAW246.7 cells treated with media
control for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining,
B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white light). Sale bar,
10µm.
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A

B

C

D

Figure 9. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM
indirubin-3’-monoxime for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR
FITC staining, B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white
light).
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A

B

C

D

Figure 10. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM BIO
for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining, B- DNA
DAPI staining, C- Merged AhR+DAPI images, D- white light).
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A

B

C

D

Figure 11. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM
E804 for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining,
B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white light).
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A

B

C

D

Figure 12. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM
PCB126, a positive AhR ligand control, for 4 hours. DAPI was used to stain
nuclear DNA. (A- AhR FITC staining, B- DNA DAPI staining, C- Merged
AhR+DAPI images, D- white light).
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A

B

C

D

Figure 13. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM
PCB104, a non planar AhR ligand negative control, for 4 hours. DAPI was used
to stain nuclear DNA. (A- AhR FITC staining, B- DNA DAPI staining, C- Merged
AhR+DAPI images, D- white light).
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Figure 14. Nitric oxide stimulation in RAW 264.7 cells treated for 24h with
indirubins or PCB-126. White bars indicate the effect of compound alone on the
macrophage model, while black bars indicate simultaneous treatment of
compound and LPS. ** represents p ≤0.01.
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Figure 15. Nitric oxide stimulation in RAW 264.7 cells treated for 48h with
indirubins or PCB-126. White bars indicate the effect of compound alone on the
macrophage model, while black bars indicate simultaneous treatment of
compound and LPS. * represents p ≤0.05.
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Figure 16. iNOS protein expression in RAW 264.7 cells following exposure to 24h
regime treatment (a) and 48h regime treatment (c). Cells were treated, lysed, and
subjected to SDS-PAGE and probed for iNOS protein (a,c) or actin protein (b,d).
Lane 1, control; lane 2, LPS control; lane 3, Io; lane 4, Io+ LPS; lane 5, BIO; lane
6, BIO + LPS; lane7, E804; lane 8, E804 +LPS, lane 9, PCB126; lane 10
PCB126 + LPS.
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Figure 17. The effects of indirubins and PCB-126 on the production of the
inflammatory cytokine IL-6 on RAW 264.7 macrophages (white bars) and LPSstimulated macrophages (black bars) treated with the 24h regime. Data
represents the mean +/- the standard error. ** represents p ≤0.01, * represents p
≤0.05 compared to appropriate control.
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Figure 18. The effects of indirubins and PCB-126 on the production of the
inflammatory cytokine IL-6 on RAW 264.7 macrophages (White bars) and LPSstimulated macrophages (Black bars) treated with the 24h regime. Data
represents the mean +/- the standard error. ** represents p ≤0.01, * represents p
≤0.05 compared to appropriate control.
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Figure 19. The effects of indirubins and PCB-126 on reactive oxygen
intermediate production in RAW 246.7 macrophages (black bars) and PMAstimulated macrophages (white bars) treated with the 24h regime with three
different concentrations of compound. Data represents the mean +/- the standard
error of the percent control cells treated without compound. ** represents p
≤0.01, * represents p ≤0.05 compared to appropriate control.
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Figure 20. The effects of indirubins and PCB-126 on reactive oxygen
intermediate production in RAW 246.7 macrophages (white bars) and PMAstimulated macrophages (black bars) treated with the 48h regime using three
different concentrations of compound. Data represents the mean +/- the standard
error of the percent control cells treated without compound. * represents p ≤0.05
compared to appropriate control.
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Figure 21. The effects of 1µM indirubins and PCB-126 on phagocytosis
incubated for 45min or 90min with FITC-labeled latex beads; treated under the
24h regime. Data represents the percent control mean from three experiments
+/- the standard error. ** represents p ≤0.01, * represents p ≤0.05 as compared
to appropriate control.
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Figure 22. The effects of 1µM indirubins and PCB-126 on phagocytosis
incubated for 45min or 90min with FITC-labeled latex beads; treated under the
48h regime. Data represents the percent control mean from three experiments
+/- the standard error. * represents p ≤0.05 as compared to appropriate control.
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Figure 23. The effects of 1µM indirubin-3’monoxime and E804 on lysozyme
activity in RAW 246.7 macrophages (white bars) and LPS-activated
macrophages (black bars) treated with the 24h regime. Data represents the
means +/- standard error. ** represents p ≤ 0.01.
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Figure 24. The effects of 1µM indirubin-3’monoxime and E804 on lysozyme
activity in RAW 246.7 macrophages (white bars) and LPS-activated
macrophages (black bars) treated with the 48h regime. Data represents the
means +/- standard error. ** represents p ≤ 0.01, * represents p ≤ 0.05.
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Figure 25. The effects of 1µM indirubins and PCB-126 on intracellular bacterial
killing in RAW 264.7 macrophages under both 24h and 48h regimes. Data
represents the mean of three experiments +/- standard error. * represents p
≤0.05 as compared to appropriate control.

79

DISCUSSION
Based on a large literature base that supports the utility of the murine
macrophage cell line, RAW 264.7, in the field of immunopharmcology, this cell
line was used to examine the effects of IO and E804, as well as BIO in some
cases, on macrophage inflammation-like functions. Because many of the
reported affects of these compounds on the biology of cells have been linked to
the AhR, this study also used the coplanar halogenated hydrocarbon PCB-126,
which is a potent AhR agonist. Moreover, when appropriate, the non-coplanar
congener PCB-104 was used as a negative control for PCB-126. This work
bridges the existing gap between the effects of treatments on alteration of gene
expression and cellular function in RAW 264.7 cells by indirubins.
As with previous work in this lab (Springs and Rice, 2006), concentrations
of 1 µM for each compound were not cytotoxic, even for up to 48 hr of treatment.
This turns out to be fortuitous because these compounds can be compared on a
molecule-to-molecule level, based on Avagadro’s number. One of the most
interesting early observations was that RAW 264.7 cells are far more sensitive to
indirubins than D74 glioma cells, suggesting that macrophages are more
sensitive than undifferentiated and anaplastic cell lines. Earlier work in this lab
used U937 cells, which are human histiocytes that can be differentiated into
macrophage-like cells via exposure to PMA. As with the RAW 264.7 cell line,
U937 cells seem to be more sensitive to indirubin toxicity as they become more
differentiated. Flow cytometry results also indicated that after 24h exposure to IO,
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E804, PCB-126 and LPS most of the cells are not undergoing apoptosis and are
viable.
It has been well established that planar hydrocarbons are ligands for the
aryl hydrocarbon receptor (AhR). The potency of AhR signaling is dependent on
the affinity of the compound for the receptor. As a case in point, TCDD has the
highest known affinity, PCB-126 and other coplanar halogenated hydrocarbons
have a potency (affinity for the AhR) ranging from 1/10th to 1/1000th of TCDD
(Kafafi, et al., 1993). Most of the known and well characterized high affinity
ligands for the AhR are anthropogenic, but the affinity of natural (endogenous?)
compounds to the AhR is still uncertain. However, recently a reporter yeast
system showed that indirubin, a planar hydrocarbon, found naturally in plants,
mollusks, bacteria, and human urine binds to the AhR with an affinity higher than
TCDD (Adachi, et al., 2001). However, in whole-cell systems the potency of
indirubin is lower than what is seen in reporter systems.
As previously reported, indirubin-3’-monoxime and other derivatives are
able to activate the aryl hydrocarbon receptor, causing it to translocate to the
nucleus (Adachi et al., 2001; Spink et al., 2003; Knockaert et al., 2004; Springs
and Rice 2006) and promote the transcription of genes associated with the
xenobiotic response element. To date, all ligands that bind to the AhR induce the
drug metabolizing CYP1A-family of enzymes. Although gene expression did not
show an increase for the cytochrome P450 family of enzymes in cells exposed to
IO or PCB-126, there was a 2.68 fold increase when treated with E804 alone for
24 hours. This is not surprising because Springs et al. (2006) reported maximum
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expression of CYP1A1 in undifferentiated U937 cells compared with low levels of
expression in fully differentiated cells also treated with LPS. Though much of the
historical attention has focused on indirubin, and it’s synthetic derivative IO, it is
clear from this study that E804 is extremely potent in terms of it’s affinity for the
AhR.
The induction of CYP genes by high affinity ligands to the AhR creates
oxidative stress within the cell due to leakage of oxygen radicals as the
monooxygenases consume oxygen (Whitlock 1993). In general, one of the most
severe toxic endpoints of strong AhR ligands is uncontrolled oxidative stress
(Radjendirane et al., 1999). Recently it was reported that AhR ligands interact
with the Nrf2 gene battery which encodes enzymes responsible for oxidative
stress (Kohle et al., 2007). Studies suggest that Nrf2 is a direct target gene for
the AhR (down-stream of the response element), and thus is transcribed along
with other members of the “gene cassette” that includes CYP1a1, Cyp1a2, and
Cyp1b1. Therefore, it is not surprising to see an increase in the expression of
heme oxygenase 1 (Hmox1) and superoxide dismutase 1 (Sod1) and other
stress related genes after exposure to IO, E804, and in PCB-126.
Both IO and E804 increased ROS production in RAW 264.7 cells after 24
hours, which is in line with Green et al. (2008) who, observed that the dioxin-like
PCBs induce Cyp1a1 and Cyp1b1 genes and intracellular production of ROS.
However, ROS production in IO and E804 treated cells was reduced after 48 hr,
indicating that several radical scavenging mechanisms were involved. Length of
time may be a factor, as activation of AhR also triggers the expression of aryl
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hydrocarbon receptor repressor, AhRR. The repressor acts as a negative
feedback loop blocking the transcription of XRE genes by competitively inhibiting
the interaction with ARNT (Evans et al., 2008). Alternatively, and more likely, the
radical scavenging system was able to abate oxidative stress. As part of the
experimental design, cells were also treated with PMA for 30 minutes just before
measuring ROS production. In primary macrophages, and especially
neutrophils, PMA acts as a diacyl-glycerol (DAG) mimic and activates protein
kinase C (PKC). PKC then activates the membrane-associated NADPH-oxidase
system, which in turn converts molecular O2 to ROS such as superoxide anion.
Superoxide anion is further reduced to hydrogen peroxide by superoxide
dismutase (SOD). Since RAW 264.7 cells are not primary macrophages, they
may not possess the ability to respond to PMA in the same fashion, therefore
explaining why PMA-treatment did not result in large amounts of ROS
generation.
Activation and translocation of the AhR to the nucleus was seen within
four hours of exposure to IO, BIO, E804, and PCB-126. PCB-104 was used as a
negative halogenated hydrocarbon control; the non-planar (globular)
configuration of the molecule inhibits its binding with the receptor. Using
antibody-labeling for the AhR has become a gold standard for showing activation
and translocation following treatment (Knockaert, et al., 2004); however, this
technique alone does not show transcription factor binding to its particular
response element. Future studies with E804 and other experimental AhR ligands
should (and will) include ChiP assays and possibly electrophoretic mobility shift
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assays (EMSAs). Still, as a screening mechanism, cytosolic vs nuclear staining
of the AhR is a quick and efficient method for identifying AhR ligands.
AhR signaling is not only involved in toxicity and oxidative stress, it plays a
role in several different pathways including cell cycle regulation, development,
and immunity (Marlowe et al., 2005). TCDD has been shown to decrease cyclin
D1 levels and CDK-dependent kinase activities (Wang et al., 1998), as have
other AhR ligands. The end effect of decreased cyclin D1 and CDK-dependent
kinases is cell cycle arrest (Reiners et al., 1999).
Hoessel et al. (1999) reported that indirubin is a cyclin-dependent kinase
inhibitor, leading to the arrest of the cell cycle by competitively binding to the ATP
catalytic site of the kinase. The interaction and concentration levels of cyclins and
cyclin-dependent kinases regulate the cell cycle progression in all eukaryotic cell
studies to date. In this study, Cyclin C, Cyclin D1, and Cyclin G were all inhibited
by the treatment of IO and E804, but treatment with PCB-126 alone did not. This
finding suggests that the halting of the cell cycle, at least in part, is independent
of AhR signaling and could be due to the regulation of cyclins and inhibition of
kinases.
The E2F family regulates the progression of the cell cycle, and there are
two subgroups divided into activating and repressing transcription factors. E2F1
is a major component in progressing the cell during the G1/S phase. The
hyperphosphorylated retinoblastoma (Rb) factor remains bound to E2F until
cyclin D/CDK4 releases its inhibition. This allows E2F to function as a positive
transcription factor increasing several factors needed to progress into the S
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phase. Studies have indicated that the activated AhR can bind to Rb and
suppress E2F activity (Puga et al., 2000). A decrease in this key factor would halt
the cell cycle in the G1/S phase. E804 dramatically decreased the expression of
E2F1 gene, indicating that E804 might be a promising anti-cancer drug with an
array of mechanisms for halting the cell cycle.
The herbal remedy in which indirubin is the active ingredient, not only
showed promising results in terms of cancer and detoxification but also chronic
inflammation. It has been previously reported that indirubin inhibits the gene
expression of inducible nitric oxide and cyclooxygenase in mast cells (Hamburger
et al., 2002). Studies have also shown that indirubin suppresses IL-6 and IFN-γ
production in mouse splenocytes and human myelomonoctic cell lines, as well as
an inhibition on induced-delayed-type hypersensitivity in mice (Kunikata et al.,
2000). The study herein showed that expression of several inflammatory genes
was decreased in cells treated with IO and E804. Notably, NOS2 and IL-6 genes
were down-regulated. This corresponds well with the functional protein assays as
seen in nitric oxide (NO) and IL-6. NO is a product of iNOS that has an important
role in killing of intracellular bacteria and other pathogens. IL-6 is a key
inflammatory cytokine that is released from macrophages in response to antigen
activating the Toll-like receptor singling pathway production of several
inflammatory mediators. The gene expression for IL-6 in E804 treated cells is
induced after 24h of treatment, however the functional assay showed an
inhibition of IL-6 activity. This finding shows the importance of researching not
only gene expression but protein function as well. E804 inhibits the cytokine
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cytoplasmic Stat signaling cascade of IL-6 by inhibiting Src kinase activity (Nam
et al., 2005). Therefore, although the gene expression of the cytokine may not
be suppressed, the down-stream signaling activity of the cytokine is modified. A
novel finding from this study indicates that E804 is a more potent inhibitor of
inflammatory functions and gene expression than its more famous IO
counterpart.
The NF-κB pathway is known as the central mediator of the innate
immune system. Most carcinogens and inflammatory agents activate NF-κB
through the degradation of its inhibitor IκB by IκB-kinase (IKK). It is then
translocated to the nucleus where it is involved in the expression of several gene
products including anti-apoptotic genes such as SURVIVIN, TRAF, BCL2, and
BCLxL, several inflammatory cytokines, and cell cycle genes including cyclin D1.
Sethi et al. (2006) reported that indirubin inhibits IKK degradation as well as the
phosporylation of p65, which is required for the translocation of NF-κB. The
study herein showed that IO and E804 had a dramatic effect on the expression of
several genes that are regulated by NF- κB including the antiapoptotic gene
BCLx, inflammatory cytokines IL-6, IL-1, and IL-18, as well as cell cycle
regulators Cyclin C and Cyclin D1. This suggests that the inhibition of NF-κB
signaling cascade could be the major mechanism by which these compounds
exert anti-inflammatory function.
The ability for RAW 264.7 macrophages to phagocytosize fluorescent
latex beads over a 45 min period was inhibited by all the indirubins. However,
after 90 min only BIO showed inhibition. It is evident from several previous

86

reports that AhR ligands inhibit phagocytosis in macrophages. van Grevenynghe
et al. (2003) reported that PAHs inhibit the macrophage’s ability to differentiate
into an active phagocytic macrophage in the presence of colony stimulating
factors. Others have shown that IO (Springs and Rice, 2006) and 3’methylcholantherene (Tewari et al., 1979) (a potent AhR ligand) suppress
phagocytosis in murine macrophages. The mechanisms in which indirubins and
other AhR ligands affect phagocytosis needs to be further examined.
Although indirubins may exert their effects through several diverse
pathways, it is becoming easier to develop indirubin derivatives with specific
activity towards one particular receptor or target. For example, brominated
indirubins bind with high affinity to GSK-3 (Meijer et al., 2003; Polychronopoulos
et al., 2004), while other derivatives bind to CDKs with higher affinity (Hoessel et
al., 1999; Moon et al., 2006). Recent studies show that methylated indirubins
have reduced binding to kinases, however they are potent ligands of the AhR
(Knockaert, et al., 2004). From a pharmacological standpoint, indirubins have
great potential for therapeutic applications by exploiting their selectivity towards a
particular kinase, receptor, or target, without the activation of other toxic
pathways. To date, however, none of the derivatives of indirubin lack AhR
binding activity, suggesting that the AhR may be a critical target, and have a
critical role in future anti-cancer and anti-inflammatory drug design approaches.
This is the first study that simultaneously examined the effects of multiple
indirubins on gene expression and corresponding cellular function in

87

macrophages. Of the indirubin derivatives examined, E804 was the most potent
in terms of biological effects.
In conclusion:



IO, E804, and BIO bind to, and activate the AhR leading to it’s
translocation to the nucleus.



IO and E804, but not PCB-126 suppressed the expression of genes
associated with cell cycling. E804 exposure drastically suppressed
expression of the E2f1 gene, indicating at least one mechanism of effect
that is independent of the AhR.



E804 is a more potent inhibitor of inflammatory genes, proteins, and
cellular functions than was has been reported for indirubin or indirubin-3’monoxime.



Indirubins affect normal cellular functions in RAW 264.7 cells in terms of
phagocytosis and intracellular killing.



This investigation revealed that E804 has more significant effects and
clinical promise than its more famous counterpart indirubin-3’-monoxime.



From a pharmacological standpoint, indirubins show great promise as
anti-cancer, anti-inflammatory, and detoxification compounds.
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APPENDIX
Scatter plots of altered gene expression in RAW 264.7 macrophages. Data
represents RFU fold changes compared to control.
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Figure 25. Scatter plot of the effects of LPS on RAW 264.7 macrophage
inflammatory related gene expression. Data represents the fold change in RFU
between LPS and control treated cells.
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Figure 26. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage
inflammatory related gene expression. Data represents the fold change in RFU
between Io and control treated cells.
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Figure 27. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage
inflammatory related gene expression. Data represents the fold change in RFU
between E804 and control treated cells.
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Figure 28. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7
macrophage inflammatory related gene expression. Data represents the RFU
fold change between PCB-126 and control treated cells.
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Figure 29. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage
inflammatory related gene expression. Data represents the fold change in RFU
between Io + LPS and LPS treated cells.
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Figure 30. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7
macrophage inflammatory related gene expression. Data represents the fold
change in RFU between E804 + LPS and LPS treated cells.
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Figure 31. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7
macrophage inflammatory related gene expression. Data represents the fold
change in RFU between PCB-126 + LPS and LPS treated cells.
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Figure 32. Scatter plot of the effects of LPS on RAW 264.7 macrophage
proliferation and carcinogenesis related gene expression. Data represents the
fold change in RFU between LPS and control treated cells.
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Figure 33. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage
proliferation and carcinogenesis related gene expression. Data represents the
fold change in RFU between Io and control treated cells.
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Figure 34. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage
proliferation and carcinogenesis related gene expression. Data represents the
fold change in RFU between E804 and control treated cells.
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Figure 35. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7
macrophage proliferation and carcinogenesis related gene expression. Data
represents the fold change in RFU between PCB-126 and control treated cells.
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Figure 37. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage
proliferation and carcinogenesis related gene expression. Data represents the
fold change in RFU between Io + LPS and LPS treated cells.
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Figure 38. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7
macrophage proliferation and carcinogenesis related gene expression. Data
represents the fold change in RFU between E804 + LPS and LPS treated cells.
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Figure 39. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7
macrophage proliferation and carcinogenesis related gene expression. Data
represents the fold change in RFU between PCB-126 + LPS and LPS treated
cells.
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Figure 40. Scatter plot of the effects of LPS on RAW 264.7 macrophage growth
arrest and senescence related gene expression. Data represents the fold change
in RFU between LPS and control treated cells.
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Figure 41. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage
growth arrest and senescence related gene expression. Data represents the fold
change in RFU between LPS and control treated cells.
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Figure 42. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage
growth arrest and senescence related gene expression. Data represents the fold
change in RFU between E804 and control treated cells.
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Figure 43. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7
macrophage growth arrest and senescence related gene expression. Data
represents the fold change in RFU between PCB-126 and control treated cells.
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Figure 44. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage
growth arrest and senescence related gene expression. Data represents the fold
change in RFU between Io + LPS and LPS treated cells.
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Figure 45. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7
macrophage growth arrest and senescence related gene expression. Data
represents the fold change in RFU between E804 + LPS and LPS treated cells.
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Figure 46. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7
macrophage growth arrest and senescence related gene expression. Data
represents the fold change in RFU between PCB-126 + LPS and LPS treated
cells.
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Figure 47. Scatter plot of the effects of LPS on RAW 264.7 macrophage
apoptotic related gene expression. Data represents the fold change in RFU
between LPS and control treated cells.
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Figure 48. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage
apoptotic related gene expression. Data represents the fold change in RFU
between Io and control treated cells.
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Figure 49. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage
apoptotic related gene expression. Data represents the fold change in RFU
between E804 and control treated cells.
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Figure 50. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7
macrophage apoptotic related gene expression. Data represents the fold change
in RFU between PCB-126 and control treated cells.
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Figure 51. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage
apoptotic related gene expression. Data represents the fold change in RFU
between Io + LPS and LPS treated cells.
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Figure 52. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7
macrophage apoptotic related gene expression. Data represents the fold change
in RFU between E804 + LPS and LPS treated cells.
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Figure 53. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7
macrophage apoptotic related gene expression. Data represents the fold change
in RFU between PCB-126 + LPS and LPS treated cells.
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Figure 54. Scatter plot of the effects of LPS on RAW 264.7 macrophage stress
related gene expression. Data represents the fold change in RFU between LPS
and control treated cells.
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Figure 55. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage stress
related gene expression. Data represents the fold change in RFU between Io and
control treated cells.
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Figure 56. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage
stress related gene expression. Data represents the fold change in RFU between
E804 and control treated cells.
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Figure 57. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7
macrophage stress related gene expression. Data represents the fold change in
RFU between PCB-126 and control treated cells.
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Figure 58. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage
stress related gene expression. Data represents the fold change in RFU between
Io + LPS and LPS treated cells.
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Figure 59. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7
macrophage stress related gene expression. Data represents the fold change in
RFU between E804 + LPS and LPS treated cells.
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Figure 60. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7
macrophage stress related gene expression. Data represents the fold change in
RFU between PCB-126 + LPS and LPS treated cells.
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